
Avalo Therapeutics (AVTX) Stock Forecast & Price Target
Avalo Therapeutics (AVTX) Analyst Ratings
Bulls say
Avalo Therapeutics has demonstrated significant upward momentum, evidenced by a pre-market increase of approximately 22%, which reflects growing market confidence in AVTX-009's potential to address hidradenitis suppurativa (HS). The upcoming LOTUS data readout is anticipated to further enhance investor sentiment as the therapeutic capabilities of AVTX-009 become increasingly recognized. Additionally, the overall market for HS therapies is expected to expand, driven by a trend towards more effective and sustained treatment options, positioning Avalo favorably within this evolving landscape.
Bears say
Avalo Therapeutics exhibits a negative outlook primarily due to observed adverse events, specifically two cases of neutropenia, including one graded as Grade 3, which may raise concerns over the safety profile of its leading asset, AVTX-009. Furthermore, potential efficacy issues are highlighted by the capability of competing therapies, such as lutikizumab, to suffer from target distraction due to their dual binding properties, which could limit their effectiveness in treating inflammatory diseases. Additionally, the historically low rates of diagnosis and treatment in the relevant market, previously ascribed to a lack of effective therapies, may continue to hinder demand for Avalo's products.
This aggregate rating is based on analysts' research of Avalo Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Avalo Therapeutics (AVTX) Analyst Forecast & Price Prediction
Start investing in Avalo Therapeutics (AVTX)
Order type
Buy in
Order amount
Est. shares
0 shares